Open Accessibility Menu

Transcranial Magnetic Stimulation

Depression and Anxiety Services in Cody

What is Treatment-resistant depression

Treatment-resistant depression is a condition that affects individuals with Major Depressive Disorder (MDD) who have tried more than two antidepressant medications and who have not responded to other types of therapies, like talk-therapy. More than 40% of patients with MDD are considered treatment-resistant. If you feel you may be experiencing treatment-resistant depression, there is hope.

What is Deep Transcranial Magnetic Stimulations (dTMS)?

We have a treatment that is FDA cleared, known as Deep TMS or Transcranial Magnetic Stimulation. It is a treatment for people with treatment-resistant depression. Deep TMS (dTMS) is a noninvasive, outpatient procedure with no systemic side effects and fits into peoples’ daily routines.

BrainsWay’s patented breakthrough treatment based on Deep TMS™ begins a new era in brain stimulation and research. This non-invasive and effective treatment activates deep brain structures by using directed electromagnetic fields that generate excitation or inhibition of neurons deep inside the brain.

BrainsWay’s Deep TMS flagship technology is based on the H-Coil, which features a novel patented structure designed to maximize electrical stimulation of deep brain regions and includes the following unique features:

  • Coil elements tangential to the head and close to target brain regions
  • Flexible base suited to head shape
  • Convergence of numerous electric pulses from various directions
  • Coil elements parallel to target bundles
  • Location of return paths of electrical impulses remote from target area

H1 Coil for Major Depression BrainsWay’s treatment was cleared by the FDA in 2013 for patients who tried any number of antidepressants with no improvement in the current depressive episode. The FDA indication is based on a unique 16-week double-blind, placebo-controlled, multi-center study which enrolled over 200 subjects, and reported a marked decline in HDRS-21 scores, as well as significant remission (32.6%) and response (38.4%) rates at the primary endpoint of the study after four weeks of acute treatment. In the study, treatment with BrainsWay’s H-1 coil helmet was proven to be safe, and the treatment was well tolerated by the majority of the study subjects. The H1 Coil is also in clinical trials at various stages for the treatment of Bipolar Disorder, Post-Traumatic Stress Disorder and Schizophrenia.

Related Providers
Related Locations